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Abstract
Co-morbid illnesses have a major inﬂuence on the epidemiology of infectious diseases. Although International Classiﬁcation of Diseases
(ICD) discharge codes are frequently used to evaluate the presence of co-morbidities in observational research, additional research is
required about their validity. We reviewed the evidence supporting the use of routinely coded administrative data for ascertainment of
co-morbid diseases with emphasis as it relates to the study of infectious diseases. A systematic Medline, Embase, and bibliographic
review were conducted in order to identify and critically appraise published (1990–2008) studies comparing administrative databases
with conventional chart review. Twenty-one co-morbidities commonly associated with infectious diseases risk were a priori selected for
speciﬁc evaluation. Of the 21 co-morbid conditions chosen, only 19 had adequate data available for evaluation. Thirteen studies were
included; only one focused on an infectious disease population. Eleven articles validated individual co-morbid conditions data in elec-
tronic administrative databases and reported a wide range of pooled sensitivity (13–82%) but overall high pooled speciﬁcity (>97%)
when compared with medical chart review. Seven articles compared Charlson Co-morbidity Index scores derived from administrative
data algorithms as compared with that calculated from medical record review and found that administrative data underscored the index
in all articles with kappa agreement ranging from 0.30 to 0.56. The small body of literature published to date suggests that electronic
administrative databases have limited validity for co-morbidity evaluation. Studies evaluating administrative database ascertainment of
co-morbidities speciﬁcally in infectious diseases research are needed.
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Introduction
The presence of co-morbid illnesses has a major inﬂuence
on the occurrence and outcome of infectious diseases [1–4].
Co-morbidity may be deﬁned as the total burden of illnesses
unrelated to the patient’s principal diagnosis. While the pres-
ence or absence of a particular co-morbidity is typically eval-
uated as a risk factor for acquiring an infectious disease in
observational research, rating scales that encompass a num-
ber of co-morbidities are commonly used to adjust for
effects on outcome [2,5–7]. The most widely used rating
scale is the Charlson Co-morbidity Index [8]. This is a
weighted index that was developed and validated to predict
1-year mortality and takes into account the number and seri-
ousness of co-morbid diseases [8]. Traditionally, the ‘gold
standard’ method for obtaining information surrounding
co-morbid illnesses has been manual individual patient record
review [5]. However, this is a labour and resource intensive
process that may preclude the assessment of co-morbidities
in many studies.
Vast amounts of medical diagnostic information, typically
coded using the International Classiﬁcation of Diseases (ICD)
system, are routinely stored in administrative electronic
healthcare databases. Many researchers, including us, have
used administrative data in order to establish the presence
of co-morbid illness in infectious diseases research [9–13]. In
addition, the Charlson Co-morbidity Index has been adapted
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for use with ICD-9-CM (ICD, 9th revision, Clinical Modiﬁca-
tion) and ICD-10 discharge codes in administrative databases
[14–16]. However, the accuracy and completeness of these
data has been raised as an important issue given the
potential for error in the process of converting diagnoses to
numerical codes for electronic storage [17–19]. Our objec-
tive was to systematically identify and appraise the published
literature evaluating the ascertainment of co-morbid condi-
tions and the Charlson Co-morbidity Index derived from
routinely coded administrative data as compared with
conventional individual clinical review with a special emphasis
as it relates to infectious diseases research.
Methods
Search strategies
A methodological search was conducted to identify published
literature comparing hospital administrative data with con-
ventional patient chart review for co-morbid illnesses and
co-morbidity indexes. Both electronic and manual searches
were used, the latter by scanning bibliographies of all evalu-
ated articles and the authors’ ﬁles. No language restriction
was used. The US National Library of Medicine’s PubMed
service and Embase were used to search for relevant elec-
tronic articles published from 1 January 1990 to 16 May
2008. Boolean operators ‘and’ ‘or’ were used in three sepa-
rate text word and exploded medical subjected headings
(MeSH) searches using combinations of ‘ICD’ and ‘comorbid-
ities’ and ‘comparison’ or ‘evaluation’ or ‘validity’ or ‘valida-
tion’ or ‘accuracy’ and ‘index’ and ‘administrative’ or
‘database’. All searches had the ﬁlter ‘abstract’.
Study selection
Titles and abstracts of all retrieved articles were screened
for inclusion. Relevant full-length articles were retrieved and
reviewed to declare if they met the predetermined inclusion
criteria by one author (J.L.). A second author (K.L.) con-
ﬁrmed the applicability of the criteria to the selected articles.
Any disagreement was settled by consensus between the
authors.
For inclusion, articles had to compare routinely collected
hospital discharge information in administrative databases
with an individualized patient or medical records review.
Studies could be either prospective or retrospective and be
in any adult or paediatric populations in primary, secondary
or tertiary healthcare settings. At least one or more of the
following validity measures had to be reported or calculable
from the data contained in the report for speciﬁc co-morbid-
ities: speciﬁcity (Sp), sensitivity (Sn), positive predictive value
(PPV) and negative predictive value (NPV). With regard to
co-morbidity indexes, hospital discharge information as
coded by general medical records staff was deﬁned as
adapted co-morbidity indexes for use with the classiﬁcation
of the International Classiﬁcation of Diseases versions 9,
9-CM, or 10 and were compared with indices calculated
using patient or clinical records review by healthcare profes-
sionals, study investigators or content experts.
Data abstraction and reporting
Population characteristics, co-morbidity and adapted ICD-
based indexes were used, and results were abstracted from
each review article onto a standardized collection form.
Because a potentially very large number of co-morbidities
could be evaluated, we selected 21 co-morbid conditions to
focus upon in analysis. These 21 conditions were selected a
priori and were based on the individual components of the
Charlson Co-morbidity Index, our experience and ten
co-morbidities most commonly assessed in population-based
studies of invasive infections [including cancer (including any
malignancy and metastatic solid tumour), heart disease
(including myocardial infarction, MI; and congestive heart fail-
ure, CHF), diabetes mellitus, stroke (CVD), lung disease,
rheumatoid arthritis, chronic renal dysfunction and/or failure,
alcoholism, organ/bone marrow transplant and AIDS]
as determined by a non-structured literature review
[3,13,20–23].
Where possible, validity measures were calculated for
administrative data as compared with conventionally deter-
mined values. Meta-DiSc (Madrid, Spain 2006) was used to
calculate corresponding conﬁdence intervals [24]. Adminis-
trative database systems with overall validity measures ‡95%
were a priori deﬁned as excellent; 80–94% as very good;
60–79% as moderate; and <60% as poor for the evaluation
of co-morbid conditions. For comparison of agreement
between co-morbidity indexes and records review diagnoses
data, Bland–Altman plots and/or Kappa statistics used were
also acceptable and were interpreted using standard criteria.
Kappa values <0.20 are interpreted as poor agreement;
0.21–0.40 as fair; 0.41–0.60 as moderate; 0.61–0.80 as good;
and 0.81–1.00 as very good.
Results
Thirteen articles fulﬁlled the predetermined inclusion criteria
and were included in the analysis as shown in Fig. 1. Table 1
summarizes each article included in this review. Most (11;
85%) of the included studies evaluated individual co-morbid
conditions among speciﬁc groups of patients including medi-
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cal [8,17,19,25]; surgical [5,17,19,25–28]; psychiatric [19];
obstetric and gynaecology [19,25]; paediatric [19]; orthopae-
dic [25]; cardiac [5,18,28–30]; and cancer patients [31].
Seven studies compared the Charlson Co-morbidity Index
score derived from administrative data as compared with
chart review [8,17,25,27,28,31,32]. A single study identiﬁed
Charlson co-
morbidities among all hospitalized patients with nosocomial
infections [25]. Although primary care centres’ administrative
data were part of our inclusion criteria, all studies were
conducted in teaching, non-teaching or community-based
hospitals.
Eleven articles validated individual co-morbid conditions
data in electronic administrative databases by comparison
with manual hospital chart review [5,8,18,19,25–27,29,30,32].
Pooled sensitivity and speciﬁcity values are presented in
Table 2. Although the speciﬁcities were excellent, the pooled
sensitivities were poor to moderate and varied signiﬁcantly
from study to study (Tables S1a and S1b). No articles
reported on the accuracy of coding for organ/bone marrow
transplant and alcohol abuse.
Seven articles compared Charlson Co-morbidity Index
scores derived from medical record data with the same index
derived from administrative data and their predictive ability
for various outcomes [8,17,25,27,28,31,32]. Results are sum-
marized in Table 3. Administrative data underscored the
Charlson Index score primarily by one point (range 12–31%)
as compared with the chart data in ﬁve articles reported
[8,17,25,27,32]. Newschaffer et al. reported administrative
claims databases underscored the Charlson Index score in
86.5% of cases and Kieszak et al. identiﬁed an administrative
database mean Charlson Index score of 0.60 compared with
1.46 by the medical chart index score [28,31].
Discussion
In this report we summarize the published literature evaluat-
ing the validity of electronic administrative data reporting of
co-morbid conditions as compared with conventional meth-
ods. The body of literature on this topic is small and we only
identiﬁed 13 heterogeneous studies. Based on the included
studies, electronic recording of co-morbidity data has limited
validity when compared with medical chart review. These
data indicate that use of electronically established co-morbid-
ity scores may underestimate the confounding effects of
co-morbid illness on the occurrence and outcome of infec-
tious diseases [33].
Administrative clinical databases are increasingly being
used in medical research. Administrative data, as compared
with conventional chart review, has advantages including
their readiness to be analysed, wide geographical coverage,
relatively complete capture of episodes of patient contact
with the health system, and perhaps most importantly mini-
mal expense. A single study outlined that the detailed review
of 1200 charts expended approximately CAN $25 000,
whereas they were able to obtain the corresponding admin-
istrative data at no cost from their health region [17].
Previous literature suggests that the quality of primary
diagnosis reporting in electronic administrative databases
appears adequate, but the accuracy of secondary, co-morbid
diagnoses is less certain [19]. We observed an overall und-
erreporting of individual co-morbid conditions within the
administrative databases compared with medical record data.
This may arise from coding error, or alternatively the lack
of well accepted, standardized guidelines for the coding of
secondary diagnoses, variability in the extent and quality
of coding both across institutions and across individual cod-
ers, co-morbidities recorded as they relate to the principal
diagnosis or procedure and the inability to distinguish
between medical conditions which existed prior to the index
hospitalization (co-morbid disease) and those which arose
anew during the hospitalization (complications). The use of
diagnostic-type codes, which allows for the determination of
primary diagnoses on admission, pre-admission co-morbidi-
ties, post-admission co-morbidities, or in-hospital complica-
1260 potentially relevant 
articles based on three searches 
1205 excluded 
• Irrelevant based on 
title and abstract 
55 potentially relevant 
based on title and abstracts  
42 excluded 
• No comparison to conventional chart review 
(n = 7) 
• Defining coding algorithms and co-morbidity 
index (n = 11) 
• Claims/Billing-based electronic database 
(n = 2) 
• Comparing primary diagnoses or 
complications or acute conditions (n = 9) 
• Review articles (n = 2) 
• Irrelevant (n = 11)  
13 articles evaluating utility of 
administrative databases compared to 
conventional chart review for co-morbid 
conditions
FIG. 1. Flow diagram summarizing article selection ﬂow and reasons
for exclusion.
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tions, may facilitate the distinction between co-morbid dis-
ease and complications [5].
Individual clinical record review has a number of limita-
tions for ascertainment of co-morbidities not limited to the
lack of standardization, frequent incompleteness of informa-
tion recorded, biases in physicians’ and other professionals’
documentation of co-morbid disease, complications occur-
ring during the hospitalization and illegibility of handwriting.
Medical professional chart reviewers often focus on the his-
tory of co-morbid conditions whereas coders are often
more sensitive to active conditions [5]. In addition, acute
clinical conditions tend to be more accurately documented
in non-teaching hospitals, but chronic coexisting diseases are
less completely recorded than at teaching hospitals [34].
Discrepancy between hospital charts and administrative
data may pose problems for the numerous epidemiological
investigations that use linked administrative data to adjust
analyses for potential confounding produced by the presence
TABLE 3. Chart review and administrative database Charlson Scores performance in outcome prediction and agreement of
Charlson Index Scores
Author Outcomes Variables Chart based index results
Administrative database
index results
Chart and administrative
index combined results
Agreement of
Charlson Index
Scores, Kappa
(CI95%)
Luthi et al. [25] 1) In-hospital mortality
2) Nosocomial infections
1) C-Statistic = 0.795a
Brier Score = 0.0282b
2) C-Statistic = 0.614 Brier
Score = 0.0537
1) C-Statistic = 0.863
Brier Score = 0.0275
2) C-Statistic = 0.645
Brier Score = 0.0528
N/A 0.30 (0.26,0.34)
Malenka et al. [27] Mortality following
prostatectomy vs. TURP
RR (CI95%) = 1.65 (1.11,2.45) RR(CI95%) = 1.72 (1.15, 2.55) RR(CI95%) = 1.63 (1.10,2.42) 0.364
(Variance = 8.95 · 10)4)
Quan et al. [17] In-hospital mortality OR (CI95%) = 1.4 (1.3,1.5) OR (CI95%) = 1.4 (1.3,1.5) N/A 0.56 (0.53,0.60)
Van Doorn
et al. [8]
1-year mortality following
index admission
RR (CI95%) = 2.64 (1.78,3.92) RR(CI95%) = 2.41 (1.92, 3.04) RR(CI95%) = 2.08 (1.61,2.69)
c
RR(CI95%) = 1.62 (1.04,2.50)
d
0.35 (N/A)
Kieszak et al. [28] 1) Inpatient mortality
2) Thirty-day mortality
3) Complications
4) Length of stay ‡ 10 days
Crude OR (p-value); Adjusted
OR (p-value)
1) 10.02 (0.004); 10.15 (0.004)
2) 3.33 (0.046); 3.25 (0.056)
3) 1.79 (0.043); 1.81 (0.042)
4) 2.16 (0.0001); 2.04 (0.0001)
Crude OR (p-value);
Adjusted OR (p-value)
1) 1.98 (0.112); 2.06 (0.092)
2) 1.92 (0.114); 1.98 (0.100)
3) 1.38 (0.142); 1.48 (0.080)
4) 1.23 (0.107); 1.25 (0.093)
N/A 0.47 (p <0.001)
Newschaffer
et al. [31]
Mortality within 63 months RR(CI95%) = 1.48 (1.23,1.78) RR(CI95%) = 1.53 (1.23,1.93) RR(CI95%) = 1.50 (1.25,1.80) 0.362 (SE = 0.073)
Levy et al. [32] N/A Mean Charlson Co-morbidity
Score = 1.87 (SD = 1.75)
Mean Charlson Co-morbidity
Score = 1.16 (SD = 1.48)
N/A Crude agreement = 53%
OR, odds ratio; RR, relative risk; SD, standard deviation; SE, standard error; TURP, transurethral resection of the prostate.
aC-Statistic—area under the receiver operating characteristic (ROC) curve, measuring the ability of the predictive model to discriminate among those who do or do not die
at the hospital and those who do have a nosocomial infection and those who do not.
bBrier score—proper score function that measures accuracy of a set of probability assessments. The lower the score, the higher the accuracy.
cCompared with chart index.
dCompared with ICD-9-CM index.
TABLE 2. Pooled validity measures of recording selected Co-morbidities in administrative data
Co-morbidity
Number of Studies
(References)
Number of
patients TP/(TP+FN)
Pooled sensitivity
(95% CI) TN/(TN+FP)
Pooled Speciﬁcity
(95% CI)
Myocardial infarctiona 8 [5,8,17,19,25–27,29] 7720 725/1521 50.4 (47.7 to 53.1) 5710/5853 97.6 (97.1 to 97.9)
Congestive heart failurea 8 [5,8,17–19,25,27,30] 7675 450/770 58.4 (54.9 to 61.9) 6739/6905 97.6 (97.2 to 97.9)
Peripheral vascular disease 8 [5,8,17–19,25,27,29] 9310 224/728 30.8 (27.4 to 34.3) 8470/8582 98.7 (98.4 to 98.9)
Cerebrovascular diseasea 9 [5,8,17–19,25–27,29,30] 9678 264/907 29.1 (26.2 to 32.2) 8680/8771 98.9 (98.7 to 99.1)
Dementia 7 [8,17–19,25,27,29] 8493 74/300 26.9 (21.4 to 33.0) 7704/7732 99.7 (99.5 to 99.8)
Chronic pulmonary diseasea 8 [5,8,17,19,25–27,29] 7720 634/1098 57.7 (54.7 to 60.6) 6450/6622 97.4 (97 to 97.8)
Rheumatoid arthritisa 2 [18,26] 1940 28/45 62.2 (46.5 to 76.2) 1889/1896 99.7 (99.3 to 99.9)
Rheumatologic disease 3 [17,19,25] 4127 29/44 65.9 (50.1 to 79.5) 4062/4083 99.5 (99.2 to 99.7)
Peptic ulcer disease 7 [8,17–19,25,27,29] 8493 162/659 24.5 (21.3 to 28.0) 7806/7834 99.7 (99.5 to 99.8)
Mild liver disease 6 [8,17–19,25,29] 8008 21/65 36.2 (24.0 to 49.9) 7373/7424 99.1 (98.8 to 99.3)
Moderate/severe liver disease 4 [8,17,19,25] 4651 23/88 26.4 (17.6 to 37.0) 4531/4563 99.3 (99.0 to 99.5)
Cirrhotic Liver Disease 2 [27,29] 2077 2/16 12.5 (1.6 to 38.3) 2058/2061 99.9 (99.6 to 100)
Diabetes Mellitusa 10 [5,8,17–19,25–27,29,30] 14814 1221/1607 78.3 (76.1 to 80.3) 12576/12715 98.7 (98.5 to 98.9)
Hemiplegia 5 [8,17–19,25] 6416 27/61 44.3 (31.5 to 57.6) 6320/6355 99.4 (99.2 to 99.6)
Renal failurea 9 [5,8,17–19,25,27,29,30] 9503 231/491 46.9 (42.4 to 51.5) 8902/9012 98.7 (98.5 to 99.0)
Any malignancya 7 [8,17–19,25,27,30] 7094 312/560 55.8 (51.6 to 60.0) 6390/6534 97.8 (97.4 to 98.1)
Metastatic solid tumoura 6 [8,17,19,25,27,29] 6728 170/208 81.8 (75.9 to 86.8) 6467/6520 99.2 (98.9 to 99.4)
HIV infection/AIDSa 5 [8,17–19,25] 6416 11/15 73 (44.9 to 92.2) 5873/5877 >99 (99.8 to 99.9)
Organ transplanta – – – – – –
Alcohol abusea – – – – – –
aCo-morbid conditions identiﬁed as risk factors for bacteremia.
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of certain co-morbid conditions. Implications for the use of
inaccurate databases include inaccurate estimation of rates of
speciﬁc disease and procedural outcomes, false classiﬁcation
of cases and controls where diagnosis is used to determine
this designation and inadequate adjustment for co-morbidity
or severity of illness leading to inaccurate risk-outcome
associations. Conditions with higher Charlson Co-morbidity
Index weightings were under-ascertained indicating that the
problem of discrepancy extends to those conditions strongly
related to poor outcomes, the conditions for which
co-morbidity adjustment is mostly required [33].
Aggregate co-morbidity measures in infectious disease
research may be used in three ways. First, they are used in
case–control and cohort studies to determine the risk fac-
tors for colonization or infection. Often, the co-morbidity
measure represents important risk factors but also an impor-
tant confounding variable that needs to be correctly adjusted
for. Second, co-morbidity measures are utilized in prediction
rules to predict colonization or infection. Co-morbidity mea-
sures are used in real time as part of infection control inter-
ventions such as identifying patients for isolation or
surveillance cultures. Only a single article compared the
prognostic value of Charlson Co-morbidity Index measures
for predicting the acquisition of nosocomial infections. Their
administrative data predicted nosocomial infections better,
compared with single-day chart review. In this study, the sin-
gle-day review data were generated based on information
documented at the initial stage of hospitalization which may
be incompletely documented in the chart, compared with
administrative data generated after discharge therefore con-
sisting of richer data for its predictive ability. The use of
ICD-9 codes to calculate the Charlson Co-morbidity Index
based on discharge data may be inappropriate to use in real-
time infection control intervention or epidemiological studies
as some co-morbidities may have developed after infection
has occurred. It may also be inappropriate in cases where
patients are observed for only one admission, where patients
have no previous admissions, or where there are long time
periods between admissions making it difﬁcult to facilitate
evaluation of previous hospitalizations [6]. A third aspect is
in the use of adjustment for mortality, length of stay and dis-
ability outcomes associated with co-morbidity for infectious
disease rates’ comparisons across healthcare centres. As all
articles primarily focused on validating all or a combination
of Charlson co-morbidities, two co-morbid conditions (alco-
holism, organ/bone marrow transplant) identiﬁed as risk
factors for bacteraemia were not evaluated.
In summary, despite the explosion in database systems
and availability of electronic data, electronic administrative
database coding of co-morbid diseases is not well character-
ized. The summary of the small body of literature on this
topic indicates that administrative databases have limited
validity in recoding for co-morbidities compared with con-
ventional chart review. Only one study evaluated these spe-
ciﬁcally in the setting of infectious diseases. As the validity of
administrative data may vary across hospitals, regions and
countries further studies are warranted to reﬁne and validate
ICD-based algorithms in administrative hospitalization
databases, especially among patients with infectious diseases.
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